Christchurch Medicines Information Service

Evidence-based information for health professionals in NZ

  • Home
  • About us
  • Enquiries
  • Bulletins
  • Medicines in specific patient groups
    • Medicines and liver impairment
    • Medicines and renal impairment
    • Medicines and elderly
    • Medicines and breastfeeding
    • Medicines and pregnancy
  • Resources
    • Complementary & Alternative Medicines
    • Therapeutic Drug Monitoring
    • Useful links
Filter results:

What's New

Pregabalin is now fully fundedFebruary 12, 2019

Pregabalin is a gabapentinoid that is now fully funded and indicated as an option for patients with neuropathic pain, as well as focal seizures and generalised anxiety (unlicensed). Pregabalin may offer advantages over gabapentin in patients where adherence to a three-times-daily regimen is problematic or where gastrointestinal absorption may be impaired. The efficacy of gabapentinoids […]

New classes of drugs fully funded from 1st Oct 2018: vildagliptin and sacubitril/valsartanOctober 3, 2018

Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor approved for the treatment of type 2 diabetes. See BPAC article for further information. Sacubitril/valsartan is approved for the treatment of symptomatic chronic heart failure with LVEF ≤40%. Sacubitril is a neprilysin inhibitor (inhibits breakdown of natriuretic peptides increasing diuresis, natriuresis, and vasodilation) and valsartan is an angiotensin-2 […]

All News

Recent Bulletins

Bulletin Archive

Pregabalin

January 14, 2019

Sacubitril + valsartan for heart failure

November 5, 2018

St John’s wort (Hypericum perforatum)

November 1, 2018

CopyrightPrivacyDisclaimerFAQs